JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

CareDx Inc

Închisă

SectorSănătate

20.78 -0.38

Rezumat

Modificarea prețului

24h

Curent

Minim

20.23

Maxim

21.68

Indicatori cheie

By Trading Economics

Venit

-5.8M

-4.1M

Vânzări

8.3M

108M

P/E

Medie Sector

14.645

67.147

EPS

0.12

Marjă de profit

-3.79

Angajați

761

EBITDA

-5.7M

1.5M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+18.89% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

119M

1.1B

Deschiderea anterioară

21.16

Închiderea anterioară

20.78

Sentimentul știrilor

By Acuity

65%

35%

314 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

CareDx Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 23:08 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 23:07 UTC

Câștiguri

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:20 UTC

Câștiguri

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr. 2026, 23:22 UTC

Câștiguri

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr. 2026, 22:52 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:33 UTC

Câștiguri

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr. 2026, 22:05 UTC

Câștiguri

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 21:57 UTC

Câștiguri

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr. 2026, 21:55 UTC

Câștiguri

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr. 2026, 21:53 UTC

Câștiguri

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparație

Modificare preț

CareDx Inc Așteptări

Obiectiv de preț

By TipRanks

18.89% sus

Prognoză pe 12 luni

Medie 24.73 USD  18.89%

Maxim 28 USD

Minim 21 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCareDx Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

2

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

14.77 / 18.49Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

314 / 347 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat